Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A, O'Malley K, Wang Z, Raj GV, Defranco DB, Hammes SR.
???displayArticle.abstract???
Although transcriptional effects of androgens have been extensively studied, mechanisms regulating transcription-independent (nongenomic) androgen actions are poorly understood. Previously, we have shown that paxillin, a multidomain adaptor protein, is a critical regulator of testosterone-induced MAPK-signaling during Xenopus oocyte maturation. Here we examine the nongenomic effects of dihydrotestosterone (DHT) in prostate cancer cells, focusing on how paxillin mediates Erk signaling and downstream physiologic actions. We show that in LnCAP cells DHT functions as a growth factor that indirectly activates the EGF-receptor (EGFR) via androgen receptor binding and matrix metalloproteinase-mediated release of EGFR ligands. Interestingly, siRNA-mediated knockdown of paxillin expression in androgen-dependent LnCAP cells as well as in androgen-independent PC3 cells abrogates DHT- and/or EGF-induced Erk signaling. Furthermore, EGFR-induced Erk activation requires Src-mediated phosphorylation of paxillin on tyrosines 31/118. In contrast, paxillin is not required for PKC-induced Erk signaling. However, Erk-mediated phosphorylation of paxillin on serines 83/126/130 is still needed for both EGFR and PKC-mediated cellular proliferation. Thus, paxillin serves as a specific upstream regulator of Erk in response to receptor-tyrosine kinase signaling but as a general regulator of downstream Erk actions regardless of agonist. Importantly, Erk-mediated serine phosphorylation of paxillin is also required for DHT-induced prostate-specific antigen mRNA expression in LnCAP cells as well as EGF-induced cyclin D1 mRNA expression in PC3 cells, suggesting that paxillin may regulate prostate cancer proliferation by serving as a liaison between extra-nuclear kinase signaling and intra-nuclear transcriptional signals. Thus, paxillin may prove to be a novel diagnostic or therapeutic target in prostate cancer.
Arnold,
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
2005, Pubmed
Arnold,
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
2005,
Pubmed Askari,
The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors.
2005,
Pubmed Brown,
Paxillin: adapting to change.
2004,
Pubmed Cai,
Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement.
2006,
Pubmed Campos,
Beta1 integrins activate a MAPK signalling pathway in neural stem cells that contributes to their maintenance.
2004,
Pubmed Carey,
Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells.
2007,
Pubmed Chen,
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.
2004,
Pubmed Cheng,
Testosterone activates mitogen-activated protein kinase via Src kinase and the epidermal growth factor receptor in sertoli cells.
2007,
Pubmed Cinar,
Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains.
2007,
Pubmed Deakin,
Paxillin comes of age.
2008,
Pubmed Dimri,
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior.
2007,
Pubmed Dobkin-Bekman,
A preformed signaling complex mediates GnRH-activated ERK phosphorylation of paxillin and FAK at focal adhesions in L beta T2 gonadotrope cells.
2009,
Pubmed Evaul,
Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells.
2008,
Pubmed Festuccia,
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
2009,
Pubmed Filardo,
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
2002,
Pubmed Fix,
Testosterone activates mitogen-activated protein kinase and the cAMP response element binding protein transcription factor in Sertoli cells.
2004,
Pubmed Frame,
Newest findings on the oldest oncogene; how activated src does it.
2004,
Pubmed Franco,
Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells.
2003,
Pubmed Fu,
Hormonal control of androgen receptor function through SIRT1.
2006,
Pubmed Gamble,
Androgens target prohibitin to regulate proliferation of prostate cancer cells.
2004,
Pubmed Goi,
An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.
2000,
Pubmed Hagel,
The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling.
2002,
Pubmed Hammes,
Extranuclear steroid receptors: nature and actions.
2007,
Pubmed Ishibe,
Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis.
2003,
Pubmed Ishibe,
Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis.
2004,
Pubmed Jamnongjit,
Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation.
2005,
Pubmed Kasai,
The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines.
2003,
Pubmed Ku,
Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells.
2000,
Pubmed Lange,
Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.
2007,
Pubmed Leevers,
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.
1994,
Pubmed Li,
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
2007,
Pubmed Lidke,
ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation.
2010,
Pubmed Lu,
The spatiotemporal pattern of Src activation at lipid rafts revealed by diffusion-corrected FRET imaging.
2008,
Pubmed Mansour,
Transformation of mammalian cells by constitutively active MAP kinase kinase.
1994,
Pubmed Mao,
Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.
1997,
Pubmed Migliaccio,
Crosstalk between EGFR and extranuclear steroid receptors.
2006,
Pubmed Migliaccio,
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.
2000,
Pubmed Nishiyama,
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
2007,
Pubmed O'Malley,
Nuclear receptor coregulators in cancer biology.
2009,
Pubmed Peterziel,
Rapid signalling by androgen receptor in prostate cancer cells.
1999,
Pubmed Qi,
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
2009,
Pubmed Rasar,
Paxillin regulates steroid-triggered meiotic resumption in oocytes by enhancing an all-or-none positive feedback kinase loop.
2006,
Pubmed
,
Xenbase Razandi,
Proximal events in signaling by plasma membrane estrogen receptors.
2003,
Pubmed Ripple,
Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
1997,
Pubmed Robinson,
Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity.
1996,
Pubmed Sastry,
Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways.
2006,
Pubmed Seong,
Visualization of Src activity at different compartments of the plasma membrane by FRET imaging.
2009,
Pubmed Suzuki,
Androgen receptor involvement in the progression of prostate cancer.
2003,
Pubmed Titus,
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
2005,
Pubmed Tremblay,
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
1996,
Pubmed Unni,
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
2004,
Pubmed Varricchio,
Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide.
2007,
Pubmed Wade,
Paxillin null embryonic stem cells are impaired in cell spreading and tyrosine phosphorylation of focal adhesion kinase.
2002,
Pubmed Walker,
FSH and testosterone signaling in Sertoli cells.
2005,
Pubmed Webb,
Paxillin phosphorylation sites mapped by mass spectrometry.
2005,
Pubmed Woodrow,
Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway.
2003,
Pubmed Xu,
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
2006,
Pubmed Xu,
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.
2009,
Pubmed Zhang,
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
2009,
Pubmed Zheng,
SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
2006,
Pubmed Zhu,
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
2008,
Pubmed
